Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)

The PROSPECTIVE trial aims to find out if using the results of Magnetic Resonance Imaging (MRI) for early breast cancer can select people to not have radiotherapy and still have a low chance of the cancer coming back after surgery. The main question it aims to answer is: \* Will cancer come back in the same breast as the original cancer in patients who have surgery for their breast cancer, but who don't have radiotherapy afterwards because the results of an MRI before surgery showed favourable characteristics for not having radiotherapy.

Trial Details

NCT ID
NCT06445738
Phase
NA
Sponsor
Breast Cancer Trials, Australia and New Zealand
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Arm A: Radiotherapy Omission
  • Arm B: Standard Treatment
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942
  • Houston, Texas, United States|29.76328,-95.36327
  • Camperdown, New South Wales, Australia|-33.88965,151.17642
  • Gateshead, New South Wales, Australia|-32.98208,151.69188
  • North Sydney, New South Wales, Australia|-33.839,151.2072

Key Eligibility Criteria

  • For inclusion in the study at Registration, participants must fulfil all of the following criteria:
  • Has provided written, informed consent to participate in the study.
  • Female participants ≥ 50 years old with histologically\* confirmed ER-positive and/or HER2-positive invasive breast cancer.
  • Has a life expectancy of at least 10 years and suitable for prolonged follow up for 10 years.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →